Johnson & Johnson MedTech

Long-term data from the DanGer Shock RCT, published in the New England Journal of Medicine, validates the durability of original findings and confirms the survival benefit of Impella CP™ heart pump increases year-over-year. Learn more: ow.ly/HwBh50ZIcH8

How does Impella™ work compared to other support devices? Dr. Navin Kapur explains how Impella™ directly unloads the left ventricle by moving blood into systemic circulation, differentiating it from IABP and VA-ECMO. Go to heartrecovery.com/en-us/acti… for more educational content.

In complex, high risk coronary disease, careful patient selection helps guide whether elective hemodynamic support can enable higher quality, more complete revascularization with less peri-procedural instability. Evidence from PROTECT series and contemporary registries shows benefit when tMCS support is applied in well selected, PROTECT like patients. heartrecovery.com/en-us/cond…

Promising data results from IMPACT (IMpella Protected cArdiaC surgery Trial), released at #AATS2026 on Monday. IMPACT focused on post-operative outcomes with planned Impella 5.5 support initiated prior to weaning patients from cardiopulmonary bypass. These pilot trial results set the stage for future study of planned Impella 5.5 use in this complex high-risk patient population that experiences significant morbidity and mortality. The evaluated use is investigational and not currently cleared or approved by the FDA. ow.ly/y4X250YVEmn

The Heart Recovery team at Johnson & Johnson MedTech is excited to celebrate another monumental moment on the road to making heart recovery the global standard of care. 400,000 patients treated globally with Impella! Recovering hearts and saving lives is our highest recognition of success, and it is humbling to think of how many lives – patients and their loved ones – we have been able to impact. Patients First!

We are thrilled to mark a significant and exciting achievement with the completion of enrollment in the United States for the Impella-Protected Cardiac Surgery Trial (IMPACT), studying the use of Impella 5.5 in cardiac surgery. The study enrolled 100 IDE participants and 292 patients in the registry! Meanwhile, Europe continues enrolling participants in their post-market study, which is expected to conclude very soon. This marks the third Impella trial that has completed enrollment in the past 12 months – a testament to our commitment to clinical research. This accomplishment would not have been possible without the invaluable support from each enrolling site dedicated to advancing the field of high-risk cardiac surgery. We would especially like to acknowledge the leadership of our National Principal Investigators in the United States, Dr. Daniel Goldstein and Dr. Edward Soltesz, as well as our National Principal Investigator in Europe, Professor Hermann Reichenspurner. Thank you, and congratulations to everyone involved!